___

• 1.Kwon H, Lok AS. Hepatitis B therapy. Nat Rev Gastroenterol Hep- atol 2011;8:275-84.
• 2.Chang LW, Liranzo M, Bergfeld WF. Cutaneous side effects asso- ciated with interferon alpha therapy:a review. Cutis 1995;56:144.
• 3.Dereure O, Raison-Peyron N, Larrey D, Blanc F, Guilhou JJ. Dif- fuse inflammatory lesions in patients treated with interferon alfa and ribavirin for hepatitis C:a series of 20 patients. Br J Dermatol 2002;147:1142-6. [CrossRef]
• 4.Kartal ED, Colak H, Ozgunes I, Usluer G. Exacerbation of psoriasis due to peginterferon alpha-2b plus ribavirin treatment of chronic active hepatitis C. Chemotherapy 2005;51:167-9. [CrossRef]
• 5.Vázquez-López F, Manjón-Haces JA, Pérez-Alvarez R, Pérez-Oli- va N. Eczema-like lesions and disruption of therapy in patients treated with interferon-alfa and ribavirin for chronic hepatitis C:the value of an interdisciplinary assessment. Br J Dermatol 2004;150:1046-7. [CrossRef]
• 6.Kartal ED, Alpat SN, Ozgunes I, Usluer G. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus in- fection. Eur J Gastroenterol Hepatol 2007;19:817-20. [CrossRef]
• 7.Koga T, Shimizu A, Nakayama J. Interferon-gamma production in peripheral lymphocytes of patients with tinea pedis:comparison of patients with and without tinea unguium. Med Mycol 2001;39:87-90. [CrossRef]
• 8.Koga T. Fungal immunology in the skin;immune response to derma- tophytes. Nippon Ishinkin Gakkai Zasshi 2009;50:151-4. [CrossRef]
• 9.Grover C, Khurana A. Onychomycosis:Newer insights in patho- genesis and diagnosis. Indian J Dermatol Venereol Leprol 2012;78:263-70. [CrossRef]
• 10.Rosenthal SA, Stritzler R, Vilafane J. Onychomycosis caused by Aspergillus fumigatus. Report of a case. Arch Dermatol 1968;97:685-7. [CrossRef]
• 11.Ramos A, Ussetti P, Laporta R, Lazaro MT, Sanchez- Romero I. Cutaneous aspergillosis in a lung transplant recipient. Transplant Infect Dis 2009;11:471-3. [CrossRef]